Literature DB >> 34048531

Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy.

Josè Vitale1, Nicola Mumoli1, Pierangelo Clerici2, Massimo De Paschale2, Isabella Evangelista1, Marco Cei1, Antonino Mazzone2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34048531      PMCID: PMC8164145          DOI: 10.1001/jamainternmed.2021.2959

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
Despite more than 150 million people becoming infected worldwide, SARS-CoV-2 reinfections are uncommon. The risk of a second infection in the population who has recovered from COVID-19 is crucial to improve quarantine management and optimize the ongoing vaccination campaign. The rate of reinfection among health care workers has been reported,[1,2] but the rate of reinfection in the general population is less clear.[3,4]

Methods

We investigated the incidence of SARS-CoV-2 primary infection and reinfection among individuals who, during the first wave of the pandemic in Italy (February to July 2020), underwent diagnostic reverse-transcriptase–polymerase chain reaction (PCR; see eAppendix in the Supplement for the platform and specifics). Symptomatic and asymptomatic patients of any age, who were recruited in several screening and contact-tracing programs, were included. We obtained the approval of the local ethics committee, which, because of the observational characteristic of the study, granted a waiver of informed consent for participants. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies. The study laboratory serves 4 hospitals (1400 beds) and one of the most severely affected sanitarian areas (560 Kmq; 470 000 inhabitants) in Lombardy, Italy, yielding 122 007 PCR test results. We defined cases (those with infection who were PCR-positive) and controls (those without infection who were PCR-negative) according to the World Health Organization guidelines; criteria are specified in eAppendix in the Supplement. The cohorts were considered to be at risk from the time of the first definition (date of positive test result for cases; date of second negative test result for controls) until the end of the observation (February 28, 2021) or a new positive PCR test result. Reinfections were defined by a second RT-PCR positivity beyond 90 days after complete resolution of the first infection and with at least 2 consecutive negative test results between episodes.[5] The 90-day window was decided on the basis of reports of RNA virus persistence until 12 weeks.[5] Statistical analyses were conducted using JMP, version 14.0 (SAS Institute), and Prism, version 9.0.2 (GraphPad). Statistical significance was set at P < .05.

Results

The baseline demographic characteristics are shown in the Table. The median (interquartile range) age of the patients was 59 (40-78) years, but positive cases were older and geographically distributed more in the industrial area of Legnano.
Table.

Population Characteristics

CharacteristicSARS-CoV-2 RT-PCR
Negative result at baseline and during follow-up (n = 12 968)Negative result that converted to positive during follow-up (n = 528)Positive result at baseline (n = 1579)
Age, y
Mean (SD)57 (23)58 (23)62 (18)
Median (IQR)59 (40-77)59 (41-78)63 (50-78)
Range0-1080-1000-107
Sex, No. (%)
Women6960 (53.7)315 (59.7)771 (48.8)
Men6008 (46.3)213 (40.3)808 (51.2)
Racial/ethnic group, No. (%)
White11 390 (87.8)494 (93.6)1449 (91.8)
Asian578 (4.5)15 (2.8)41 (2.6)
Black466 (3.6)7 (1.3)22 (1.4)
Latinx506 (3.9)12 (2.3)59 (3.7)
Other28 (0.2)08 (0.5)
Health district, No. (%)
Legnano7441 (57.4)293 (55.4)798 (50.5)
Magenta4203 (32.4)192 (36.4)728 (46.1)
Abbiategrasso737 (5.7)20 (3.8)47 (3.0)
Cuggiono587 (4.5)23 (4.4)6 (0.4)
No. of tests, median (IQR)3 (3-4)4 (4-5)3 (3-5)
Person-day of follow-up3 499 503112 974496 586
Inpatients, No. (%)3547 (27.4)308 (58.3)1176 (74.5)
Symptomatic, No (%)5554 (42.8)371 (70.3)1105 (70.0)

Abbreviations: IQR, interquartile range; RT-PCR, reverse-transcription–polymerase chain reaction.

Abbreviations: IQR, interquartile range; RT-PCR, reverse-transcription–polymerase chain reaction. During the follow-up (mean [SD], 280 [41] days) 5 reinfections (0.31%; 95% CI, 0.03%-0.58%) were confirmed in the cohort of 1579 positive patients. Most of these patients were evaluated, treated, and followed in hospitals or dedicated COVID-19 ambulatories.[6] Only 1 was hospitalized, and 4 patients had a close relationship (2 patients work in hospitals, 1 patient underwent transfusions every week, and 1 patient retired in a nursing home) with health facilities. The mean (SD) interval between primary infection and reinfection was longer than 230 (90) days. Of 13 496 persons who initially were not infected with SARS-CoV-2, 528 (3.9%; 95% CI, 3.5%-4.2%) subsequently developed a primary infection. The incidence density per 100 000 person days was 1.0 (95% CI, 0.5-1.5) for reinfections compared with 15.1 (95% CI, 14.5-15.7) for new infections, while the incidence rate ratio adjusted for age, sex, ethnicity, and the sanitarian area was 0.07 (95% CI, 0.06-0.08). After analyzing the cumulative incidence during follow-up, we confirmed that the 2 cohorts were significantly different (hazard ratio, 0.06; 95% CI, 0.05-0.08; log-rank test P < .001) (Figure).
Figure.

Cumulative Incidence of SARS-Cov-2 Infection

RT-PCR indicates reverse-transcriptase–polymerase chain reaction.

Cumulative Incidence of SARS-Cov-2 Infection

RT-PCR indicates reverse-transcriptase–polymerase chain reaction.

Discussion

The study results suggest that reinfections are rare events and patients who have recovered from COVID-19 have a lower risk of reinfection. Natural immunity to SARS-CoV-2 appears to confer a protective effect for at least a year, which is similar to the protection reported in recent vaccine studies. However, the observation ended before SARS-CoV-2 variants began to spread, and it is unknown how well natural immunity to the wild-type virus will protect against variants.
  52 in total

1.  Risk of SARS-CoV-2 Reinfection 18 Months After Primary Infection: Population-Level Observational Study.

Authors:  Maria Elena Flacco; Graziella Soldato; Cecilia Acuti Martellucci; Giuseppe Di Martino; Roberto Carota; Antonio Caponetti; Lamberto Manzoli
Journal:  Front Public Health       Date:  2022-05-02

2.  Immunomodulatory LncRNA on antisense strand of ICAM-1 augments SARS-CoV-2 infection-associated airway mucoinflammatory phenotype.

Authors:  Dinesh Devadoss; Arpan Acharya; Marko Manevski; Dominika Houserova; Michael D Cioffi; Kabita Pandey; Madhavan Nair; Prem Chapagain; Mehdi Mirsaeidi; Glen M Borchert; Siddappa N Byrareddy; Hitendra S Chand
Journal:  iScience       Date:  2022-06-30

3.  "Long COVID" results after hospitalization for SARS-CoV-2 infection.

Authors:  Marta Rigoni; Emanuele Torri; Giandomenico Nollo; Livia Delle Donne; Sebastiano Rizzardo; Lorenza Lenzi; Andrea Falzone; Susanna Cozzio
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

4.  Making waves: Wastewater surveillance of SARS-CoV-2 in an endemic future.

Authors:  Fuqing Wu; Wei Lin Lee; Hongjie Chen; Xiaoqiong Gu; Franciscus Chandra; Federica Armas; Amy Xiao; Mats Leifels; Steven F Rhode; Stefan Wuertz; Janelle Thompson; Eric J Alm
Journal:  Water Res       Date:  2022-05-03       Impact factor: 13.400

5.  The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis.

Authors:  Tawanda Chivese; Joshua T Matizanadzo; Omran A H Musa; George Hindy; Luis Furuya-Kanamori; Nazmul Islam; Rafal Al-Shebly; Rana Shalaby; Mohammad Habibullah; Talal A Al-Marwani; Rizeq F Hourani; Ahmed D Nawaz; Mohammad Z Haider; Mohamed M Emara; Farhan Cyprian; Suhail A R Doi
Journal:  Pathog Glob Health       Date:  2022-01-31       Impact factor: 3.735

6.  The new normal: Covid-19 risk perceptions and support for continuing restrictions past vaccinations.

Authors:  Maja Graso
Journal:  PLoS One       Date:  2022-04-08       Impact factor: 3.752

7.  COVID-19 transmission dynamics underlying epidemic waves in Kenya.

Authors:  Samuel P C Brand; John Ojal; Rabia Aziza; Vincent Were; Emelda A Okiro; Ivy K Kombe; Caroline Mburu; Morris Ogero; Ambrose Agweyu; George M Warimwe; James Nyagwange; Henry Karanja; John N Gitonga; Daisy Mugo; Sophie Uyoga; Ifedayo M O Adetifa; J Anthony G Scott; Edward Otieno; Nickson Murunga; Mark Otiende; Lynette I Ochola-Oyier; Charles N Agoti; George Githinji; Kadondi Kasera; Patrick Amoth; Mercy Mwangangi; Rashid Aman; Wangari Ng'ang'a; Benjamin Tsofa; Philip Bejon; Matt J Keeling; D James Nokes; Edwine Barasa
Journal:  Science       Date:  2021-10-07       Impact factor: 47.728

8.  Repeat positive SARS-CoV-2 RNA testing in nursing home residents during the initial 9 months of the COVID-19 pandemic: an observational retrospective analysis.

Authors:  Jillian N Armstrong; Lauren Campbell; Terry Rabatsky-Her; Vivian Leung; Sunil Parikh
Journal:  Lancet Reg Health Am       Date:  2021-08-21

Review 9.  SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.

Authors:  Ralf Duerr; Keaton M Crosse; Ana M Valero-Jimenez; Meike Dittmann
Journal:  Microorganisms       Date:  2021-06-27

10.  Reinfection with SARS-CoV-2 in solid-organ transplant recipients: Incidence density and convalescent immunity prior to reinfection.

Authors:  Stephen Morris; Shweta Anjan; Suresh Pallikkuth; Paola Frattaroli; Steve Courel; Anmary Fernandez; Akina Natori; Lilian Abbo; Savita Pahwa; Giselle Guerra; Yoichiro Natori
Journal:  Transpl Infect Dis       Date:  2022-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.